Status: Recruiting
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: Up to 50Biological sex: AllType: InterventionalSponsor: University of FloridaUpdated: Sep 1, 2026Locations: 4
Eligibility criteria
Age < 22 years of age at the time of diagnosis of malignancy [+32]
Prior myeloablative allogeneic HCT [+28]